Toggle navigation
Home
Search
Services
Blog
Contact
About
No. 73 a Phase Iia Cancer Prevention Trial of the Ppar/ Agonist Piogli-261015000
University of Minnesota Twin Cities, Minneapolis, MN, United States
Search grants from University of Minnesota Twin Cities
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Fred Hutchinson Cancer Research Center
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
FACTORS IN AGING: Best Practices in Archiving and Sharing Longitudinal Data Resources on Aging
Identifying and characterizing new components for Wnt signaling
Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care:I-CARE
Molecular Pathogenesis of Radiation Enteropathy
GOALI: Robust Quality Control Tools for Cyber-Physical Manufacturing Systems: Assessing and Eliminating Cyber-Attack Vulnerabilities
Recently added grants:
Single-Neuron Marking in the Study of Abnormal Cochleas
Clinical Protocol and Data Management
A novel opioid receptor antagonist for treating abuse and overdose
Protocol Review and Monitoring System
Signaling and Biotechology Program
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Division of Cancer Prevention And Control (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN015000-003
Application #
7329488
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2006
Total Cost
Indirect Cost
Institution
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Related projects
NIH 2006
N01 CN
No. 73 a Phase Iia Cancer Prevention Trial of the Ppar/ Agonist Piogli-261015000
/ University of Minnesota Twin Cities
NIH 2004
N01 CN
No. 73 a Phase Iia Cancer Prevention Trial of the Ppar/ Agonist Piogli-261015000
/ University of Minnesota Twin Cities
Publications
Rosas, R R; Cole, K A; Darrah, L et al.
(2012)
A comparison of screening methods in two early phase oral leukoplakia clinical trials.
Oral Dis 18:720-3
Comments
Be the first to comment on this grant